Immunoreceptors and Immunotherapy
From
16.06.2024 09:00
until 20.06.2024 17:30
×
With great honor the board of the Dutch Society for Immunology (NVvI-DSI) announces that Prof. dr. John Haanen is awarded the van Loghem Laureate 2025.
John is consultant medical oncologist and scientific group leader of the Research Theme Immunotherapy and Director of the Center for Cellular Therapy at the Netherlands Cancer Institute (NKI), Amsterdam. He is Professor in translational immunotherapy of cancer at Leiden University Medical Center, Netherlands, and Head of Melanoma Clinic at Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland. He earned his PhD from Leiden University in November 1991. During his doctoral research, he conducted studies at the prestigious DNAX Research Institute in Palo Alto, California, where he played a major role in the first characterization of human Th1 cells (Haanen et al J. Exp. Med. 1991). Subsequently, he exploited his understanding of human immunology as well as his commitment to immuno-oncology to drive the clinical development of both immune checkpoint blockade and tumor-infiltrating lymphocyte (TIL) therapy, and successfully translating these innovations into clinical practice. As a leading innovator in immuno-oncology, John co-authored over 500 papers and has received a great number of national and international awards, including the Memorial Sloan Kettering Cancer Center Woodward Professorship Award, the 2024 Bob Pinedo Cancer Care Award, and the 2024 ESMO Lifetime Achievement Award. In view of these outstanding scientific contributions to the field of immunology, he will give the van Loghem Lecture at the NVvI-DSI annual meeting 2025.
